EP3917538
Deoxýsýtídínafleiður til notkunar við krabbameinsmeðferðir
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.2.2020EP published:
12.7.2023EP application number:
20703447.1
EP translation filed:
9.8.2023Grant published:
15.9.2023EPO information:
European Patent Register
Max expiry date:
2.2.2040Expiry date:
2.2.2027Next due date:
28.2.2027
Title in English:
DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIESLanguage of the patent:
English
Timeline
Today
3.2.2020EP application
12.7.2023EP Publication
9.8.2023Translation submitted
15.9.2023Registration published
2.2.2027Expires
Owner
Name:
TETRAGON BIOSCIENCES LTDAddress:
Modi‘in Technology Park 2 HaMa‘ayan Street, Modi‘in, 7177871, IL
Inventor
Name:
ROBERTSON, Adam BrianAddress:
0585 Oslo, NO
Name:
PRIKRYLOVA, TereziaAddress:
0585 Oslo, NO
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201901427Date:
1.2.2019Country:
GB
Classification
Categories:
A61K 31/7068, A61K 31/7072, A61K 45/06, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 16.2.2024
Expires: 2.2.2025
Payer: CPA Global (Patrafee) AB
Number: 6
Paid: 24.3.2025
Expires: 2.2.2026
Payer: CPA Global (Patrafee) AB
Number: 7
Paid: 26.2.2026
Expires: 2.2.2027
Payer: CPA Global (Patrafee) AB